Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for Coeptis Therapeutics Holdings (COEP) over the last 4 years, with Q3 2025 value amounting to $315000.0.

  • Coeptis Therapeutics Holdings' Share-based Compensation rose 53636.36% to $315000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 8471.51%. This contributed to the annual value of $1.3 million for FY2024, which is 6993.41% down from last year.
  • According to the latest figures from Q3 2025, Coeptis Therapeutics Holdings' Share-based Compensation is $315000.0, which was up 53636.36% from $1.8 million recorded in Q2 2025.
  • Coeptis Therapeutics Holdings' Share-based Compensation's 5-year high stood at $3.5 million during Q1 2022, with a 5-year trough of $49500.0 in Q3 2024.
  • Over the past 4 years, Coeptis Therapeutics Holdings' median Share-based Compensation value was $541750.0 (recorded in 2024), while the average stood at $897104.1.
  • Per our database at Business Quant, Coeptis Therapeutics Holdings' Share-based Compensation crashed by 9069.2% in 2024 and then soared by 53636.36% in 2025.
  • Quarter analysis of 4 years shows Coeptis Therapeutics Holdings' Share-based Compensation stood at $363500.0 in 2022, then rose by 15.98% to $421601.0 in 2023, then tumbled by 57.38% to $179676.0 in 2024, then skyrocketed by 75.32% to $315000.0 in 2025.
  • Its Share-based Compensation was $315000.0 in Q3 2025, compared to $1.8 million in Q2 2025 and $597731.0 in Q1 2025.